Introducing the CDRA chip, a game-changing technology that rapidly induces drug resistance in melanoma, brain tumor, and bone marrow cancer cells within 1-2 weeks. By utilizing this chip, we identified mutated and highly expressed genes associated with drug resistance through genome sequencing. Our research demonstrates the potential of the CDRA chip to revolutionize drug resistance research and enhance drug screening and personalized treatment strategies.

Introducing the Multi-Inlet Spheroid Generator (MSG), a groundbreaking device designed for stable addition of liquid-containing drugs or cells into tumor spheroids. The MSG enables precise control over volume and sequence of solution injections without increasing pressure on the hanging drop. Through testing with patient-derived cancer cells, it showcases remarkable versatility for high-throughput drug screening and faithfully recapitulating the tumor microenvironment.